Featured

TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022

Find out more large-arrow.png

Pipeline

Sareum has an innovative pipeline of drug development candidates.

Find out more large-arrow.png

Presentationssmall-arrow.png

BioTrinity, April 2022 (Slides)
IMC Half Year Results, Feb 2022 (Slides)
IMC Full Year Results, Oct 2021 (Slides)
LSX World Congress, Feb 2021 (Video)